search
Back to results

Metformin Treatment in Polycystic Ovary Syndrome (PCOS)

Primary Purpose

Polycystic Ovary Syndrome

Status
Unknown status
Phase
Not Applicable
Locations
Study Type
Interventional
Intervention
Metformin ER
Sponsored by
Massachusetts General Hospital
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional basic science trial for Polycystic Ovary Syndrome focused on measuring Polycystic Ovary Syndrome, PCOS, Acne, Infertility, Irregular menses, Irregular period, Mitochondria, Metabolism

Eligibility Criteria

18 Years - 40 Years (Adult)FemaleDoes not accept healthy volunteers

Inclusion Criteria:

  • Polycystic ovary syndrome
  • No hormonal or antidiabetic medications for 1 month
  • Good general health

Exclusion Criteria:

  • Smoker
  • Acute infection or chronic disease
  • Diabetes
  • Pregnant or trying to get pregnant over next half year
  • Bleeding disorders
  • Any metal or foreign implants (e.g., aneurysm clips, ear implants, heart pacemakers or defibrillators)

Sites / Locations

    Arms of the Study

    Arm 1

    Arm Type

    Experimental

    Arm Label

    Metformin

    Arm Description

    Metformin ER 1500 mg per day treatment for 12 weeks

    Outcomes

    Primary Outcome Measures

    Muscle Metabolism/Mitochondrial Function
    The change in mitochondrial activity before and after metformin treatment will be analyzed in relationship to the clinical response to 3 months of metformin treatment (i.e., clinical response to metformin = changes in glucose metabolism, hormone levels, and ovulation response)

    Secondary Outcome Measures

    Genetic risk variants affecting mitochondrial function/metabolism
    Blood will be analyzed for differences in genes between patients and its relationship to mitochondrial function.

    Full Information

    First Posted
    July 17, 2014
    Last Updated
    August 14, 2018
    Sponsor
    Massachusetts General Hospital
    Collaborators
    Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD), University of Utah
    search

    1. Study Identification

    Unique Protocol Identification Number
    NCT02198417
    Brief Title
    Metformin Treatment in Polycystic Ovary Syndrome (PCOS)
    Official Title
    Effects of Metformin on Mitochondrial Function in Polycystic Ovary Syndrome
    Study Type
    Interventional

    2. Study Status

    Record Verification Date
    August 2018
    Overall Recruitment Status
    Unknown status
    Study Start Date
    July 2014 (undefined)
    Primary Completion Date
    September 2020 (Anticipated)
    Study Completion Date
    December 2020 (Anticipated)

    3. Sponsor/Collaborators

    Responsible Party, by Official Title
    Principal Investigator
    Name of the Sponsor
    Massachusetts General Hospital
    Collaborators
    Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD), University of Utah

    4. Oversight

    Data Monitoring Committee
    No

    5. Study Description

    Brief Summary
    PCOS occurs when a woman does not release an egg regularly each month, causing her periods to be irregular. Women with PCOS can also have increased hair growth on the face and body, acne, head balding, infertility, pre-diabetes, and diabetes. PCOS is commonly treated with oral contraceptive pills (also known as the birth control pills). Sometimes, a medication called metformin is also used to treat PCOS, especially if a woman has evidence of insulin resistance or if fertility is desired. Unfortunately, metformin works in only some women with PCOS. The mechanism through which metformin works in PCOS is not clear and it difficult to predict who will benefit from metformin treatment and who will not. The investigators are doing this research study to look at how the medication metformin affects the cells in the body of patients with PCOS. Specifically, the investigators will look at how metformin affects the mitochondria. Mitochondria are the part of cells that produce fuel (energy) for other cells and play a role in metabolism. The investigators would like to see whether there is a relationship between mitochondrial activity and symptoms of polycystic ovary syndrome (PCOS) before and after treatment with metformin. They would also like to study whether genes affect the response to metformin in women with PCOS.
    Detailed Description
    Women who are eligible to enroll in this study will be treated with the medication metformin for 12 weeks. Before and after treatment with metformin, the following will be assessed: Weight, blood pressure, waist circumference Lipids (cholesterol) Hormone levels (including testosterone and other androgens) IV glucose tolerance test (to assess for early evidence of insulin resistance) Effect of metformin on muscle mitochondria (this will involve one MRI scan and one muscle biopsy each before and after treatment with metformin) Ovulation will be closely monitored at least twice a month with pelvic ultrasounds and blood tests for estrogen and progesterone levels.

    6. Conditions and Keywords

    Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
    Polycystic Ovary Syndrome
    Keywords
    Polycystic Ovary Syndrome, PCOS, Acne, Infertility, Irregular menses, Irregular period, Mitochondria, Metabolism

    7. Study Design

    Primary Purpose
    Basic Science
    Study Phase
    Not Applicable
    Interventional Study Model
    Single Group Assignment
    Masking
    None (Open Label)
    Allocation
    N/A
    Enrollment
    20 (Anticipated)

    8. Arms, Groups, and Interventions

    Arm Title
    Metformin
    Arm Type
    Experimental
    Arm Description
    Metformin ER 1500 mg per day treatment for 12 weeks
    Intervention Type
    Drug
    Intervention Name(s)
    Metformin ER
    Other Intervention Name(s)
    Glucophage
    Intervention Description
    Treatment with metformin ER for 12 weeks
    Primary Outcome Measure Information:
    Title
    Muscle Metabolism/Mitochondrial Function
    Description
    The change in mitochondrial activity before and after metformin treatment will be analyzed in relationship to the clinical response to 3 months of metformin treatment (i.e., clinical response to metformin = changes in glucose metabolism, hormone levels, and ovulation response)
    Time Frame
    3 months
    Secondary Outcome Measure Information:
    Title
    Genetic risk variants affecting mitochondrial function/metabolism
    Description
    Blood will be analyzed for differences in genes between patients and its relationship to mitochondrial function.
    Time Frame
    3 months

    10. Eligibility

    Sex
    Female
    Minimum Age & Unit of Time
    18 Years
    Maximum Age & Unit of Time
    40 Years
    Accepts Healthy Volunteers
    No
    Eligibility Criteria
    Inclusion Criteria: Polycystic ovary syndrome No hormonal or antidiabetic medications for 1 month Good general health Exclusion Criteria: Smoker Acute infection or chronic disease Diabetes Pregnant or trying to get pregnant over next half year Bleeding disorders Any metal or foreign implants (e.g., aneurysm clips, ear implants, heart pacemakers or defibrillators)
    Overall Study Officials:
    First Name & Middle Initial & Last Name & Degree
    Corrine Welt, M.D.
    Organizational Affiliation
    Massachusetts General Hospital
    Official's Role
    Principal Investigator

    12. IPD Sharing Statement

    Citations:
    PubMed Identifier
    24606093
    Citation
    Pau CT, Keefe C, Duran J, Welt CK. Metformin improves glucose effectiveness, not insulin sensitivity: predicting treatment response in women with polycystic ovary syndrome in an open-label, interventional study. J Clin Endocrinol Metab. 2014 May;99(5):1870-8. doi: 10.1210/jc.2013-4021. Epub 2014 Feb 25.
    Results Reference
    background

    Learn more about this trial

    Metformin Treatment in Polycystic Ovary Syndrome (PCOS)

    We'll reach out to this number within 24 hrs